Salud financiera de hoja de balance de EyePoint Pharmaceuticals
Salud financiera controles de criterios 6/6
EyePoint Pharmaceuticals tiene un patrimonio de los accionistas total de $266.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $355.2M y $88.9M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$299.35m |
| Patrimonio | US$249.93m |
| Total pasivo | US$79.31m |
| Activos totales | US$329.25m |
Actualizaciones recientes sobre salud financiera
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Recent updates
EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Apr 02How Many EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Do Institutions Own?
Feb 22EyePoint Pharma announces potential capital raise
Feb 01Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($344.8M) de EYPT superan a sus pasivos a corto plazo ($63.3M).
Pasivo a largo plazo: Los activos a corto plazo de EYPT ($344.8M) superan a sus pasivos a largo plazo ($25.6M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: EYPT está libre de deudas.
Reducción de la deuda: EYPT no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 46.8%.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: EYPT tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.
Pronóstico de cash runway: EYPT dispone de suficiente cash runway para 2.9 años si el flujo de caja libre sigue creciendo a tasas históricas de 1.9% cada año.